Industry
Biotechnology
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from totan@benzinga.com
August 04, 2023 | 2:26 pm
Portfolio Pulse from Happy Mohamed
August 04, 2023 | 1:02 pm
Portfolio Pulse from Lisa Levin
July 18, 2023 | 5:00 pm
Portfolio Pulse from richadhand@benzinga.com
July 10, 2023 | 12:33 pm
Portfolio Pulse from Benzinga Insights
June 28, 2023 | 8:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.